About Cerus:
Cerus aims to be the global leader and trusted partner of blood centers and hospitals whose technology, services, and commitment are the lifeblood of safe and accessible blood for patients around the world.
The temp RA opportunity is 6 - 18 months.
Summary & Scope of Position:
Perform plasma function assays, including under GLP conditions for regulatory submissions.
Primary Responsibilities:
- Execute experiments, analyze data, and interpret results, either independently or as a team member (including experiments for product claims and regulatory submissions).
- Prepare and manipulate various blood products, including plasma, platelets and cryoprecipitate.
- Analyze data and results for research experiments and GLP studies.
- Perform and appropriately document GLP and notebook studies.
- Participate in the validation of new methods.
- May present results of data at departmental or project meetings.
- Maintain laboratory instruments.
- Document work in laboratory notebook in an accurate and timely manner.
- Perform other duties as required.
Qualifications/Requirements/Skills:
- Bachelor’s degree or equivalent certification in a scientific discipline.
- Experience working in a lab environment (GLP or other regulated environment preferred).
- Proficient in writing reports.
- Strong attention to detail and accuracy.
- Good analytical skills; problem-solving, troubleshooting.
- Ability to work independently and in a team environment.
- Flexible; ability to adapt to changing priorities.
- Good communication skills (encompasses verbal, written, interpersonal).
- Good time management (scheduling, task prioritization).
All qualified applicants will receive consideration for employment without regard to race, sex, color, religion, sexual orientation, gender identity, national origin, protected veteran status, or on the basis of disability.
Similar Jobs
What We Do
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.







